Jane Street Group LLC Sells 18,570 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA)

Jane Street Group LLC reduced its position in Ikena Oncology, Inc. (NASDAQ:IKNA) by 33.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,270 shares of the company’s stock after selling 18,570 shares during the period. Jane Street Group LLC owned approximately 0.08% of Ikena Oncology worth $64,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of IKNA. Vanguard Personalized Indexing Management LLC purchased a new stake in Ikena Oncology during the 2nd quarter valued at approximately $30,000. AQR Capital Management LLC bought a new position in shares of Ikena Oncology during the second quarter valued at approximately $36,000. FMR LLC lifted its stake in shares of Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after purchasing an additional 18,607 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ikena Oncology during the 2nd quarter worth approximately $75,000. Finally, BBR Partners LLC raised its stake in Ikena Oncology by 550.0% in the third quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock valued at $225,000 after buying an additional 110,000 shares during the last quarter. 75.00% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on IKNA shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Ikena Oncology in a research report on Monday, November 11th. Wedbush reiterated a “neutral” rating and issued a $2.00 target price on shares of Ikena Oncology in a research report on Monday, December 23rd.

Ikena Oncology Stock Performance

Shares of IKNA opened at $1.49 on Thursday. The company has a market capitalization of $71.90 million, a P/E ratio of -1.21 and a beta of 0.49. Ikena Oncology, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $1.94. The business’s 50-day moving average is $1.66 and its two-hundred day moving average is $1.68.

Ikena Oncology (NASDAQ:IKNA) last announced its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.08. Analysts forecast that Ikena Oncology, Inc. will post -0.91 EPS for the current year.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.